Use of CBx cannabinoid receptor modulators as potassium channel modulators

Abstract

The invention is directed to the use of at least one CBx modulator wherein the CBx modulator is selected from the group consisting of CB1 agonists; CB2 agonists; CB2 partial agonists; CB2 antagonists; CB2 inverse agonists; and dually acting compounds which are both a CB1 agonist and a CB2 agonist; and mixtures thereof, as KATP channel modulator for the prophylaxis, treatment, delayed progression, delayed onset and/or inhibition of a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans. The invention further relates to methods of treating, preventing, delaying progression of, delaying onset of and/or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans comprising administering to a subject in need thereof an effective amount of at least one CBx modulator having KATP channel modulating properties.

Description

technical field [0001] The present invention relates to CB x Regulator as K ATP New uses of channel modulators. The present invention also relates to methods of treating, preventing, delaying the progression of, delaying the onset of, and / or inhibiting disease, said disease being obesity, diabetes, metabolic syndrome, syndrome X, insulinoma in mammals and humans , familial hyperinsulinemic hypoglycemia, male pattern baldness, detrusor hyperactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina pectoris, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral Vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence, the method comprising administering to a subject in need thereof an effective amount of at least one of the K ATP CB of channel modulator x Conditioner. Background technique [0002] Obesity in the present invention is meant to include any increase i...

AI Technical Summary

Problems solved by technology

However, according to information from the American Heart Federation, the term "Syndrome X" additionally refers to a cardiac condi...

Images